Sarepta Therapeutics Inc (SRPT) Receives Average Rating of “Buy” from Analysts

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have been given a consensus rating of “Buy” by the twenty-eight research firms that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, twenty-three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $185.60.

Several research firms recently issued reports on SRPT. BidaskClub raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 29th. Cantor Fitzgerald began coverage on shares of Sarepta Therapeutics in a report on Monday, October 1st. They set an “overweight” rating and a $217.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $200.00 price target (up from $187.00) on shares of Sarepta Therapeutics in a report on Wednesday, September 26th. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics to $196.00 and set a “buy” rating for the company in a report on Monday, September 24th. Finally, BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, September 24th.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 16,000 shares of the stock in a transaction dated Wednesday, August 15th. The shares were acquired at an average cost of $125.26 per share, for a total transaction of $2,004,160.00. Following the completion of the transaction, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at $50,010,055. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Sandesh Mahatme sold 107,524 shares of the stock in a transaction that occurred on Wednesday, October 24th. The shares were sold at an average price of $127.74, for a total transaction of $13,735,115.76. Following the completion of the sale, the chief financial officer now owns 48,381 shares in the company, valued at $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in SRPT. Kovack Advisors Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $217,000. First Trust Advisors LP boosted its position in Sarepta Therapeutics by 273.2% during the third quarter. First Trust Advisors LP now owns 237,387 shares of the biotechnology company’s stock worth $38,340,000 after acquiring an additional 173,782 shares during the last quarter. Atria Investments LLC acquired a new stake in Sarepta Therapeutics during the third quarter worth approximately $269,000. Catalyst Capital Advisors LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $2,445,000. Finally, First Quadrant L P CA acquired a new stake in Sarepta Therapeutics during the third quarter worth approximately $130,000. Institutional investors and hedge funds own 89.84% of the company’s stock.

NASDAQ SRPT traded down $6.22 during trading hours on Friday, hitting $126.78. 75,963 shares of the stock were exchanged, compared to its average volume of 1,075,023. The stock has a market capitalization of $9.17 billion, a P/E ratio of -77.16 and a beta of 1.59. Sarepta Therapeutics has a 12-month low of $50.51 and a 12-month high of $176.50. The company has a quick ratio of 7.84, a current ratio of 8.85 and a debt-to-equity ratio of 0.65.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.29). The firm had revenue of $78.49 million for the quarter, compared to analysts’ expectations of $78.84 million. Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. On average, equities research analysts expect that Sarepta Therapeutics will post -4.38 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Read More: What is a stock buyback?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply